AIDX
20/20 Biolabs, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.49
+4.75%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 8Sep 11Sep 16Sep 21
Key dataSep 21, 2026
Open$0.51
From 52W high−97.96%
Volume56.00
Market cap$6.22M
P/E (TTM)—
P/S (TTM)3.0x
Div yield—
Key dataSep 21, 2026
Open
$0.51
From 52W high
−97.96%
Volume
56.00
Market cap
$6.22M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
P/E (TTM)
—
RSI (14)
40.3
MomentumView details →
1D Return
+4.75%
YTD Return
—
Similar companies
Latest newsMore news →
Nasdaq notified 20/20 Biolabs, Inc. on September 3, 2026 that it failed to comply with the $2.5 million stockholders' equity requirement under Listing Rule 5550(b)(1), giving the company 45 calendar days to submit a compliance plan.11d agoBioLabs announced Carmen Schicklberger as site director for BioLabs Rochester, MN, and Geof Hannigan as Mayo Clinic's director of startup engagement.19d agoBioLabs Rochester, MN announced it will open its 17,000-square-foot shared laboratory and office facility in September 2026, with recruitment underway for resident companies.19d ago